Publications - 'P'
Publications 626 - 650 de 2458
| Titre | DOI |
|---|---|
|
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment C. Rolfo; J. de Vos-Geelen; N. Isambert; R. Molife; J.H.M. Schellens; J. De Greve; L. Dirix; P. Grundtvig-Sorensen; G. Jerusalem; K. Leunen; M. Mau-Sorensen; R. Plummer; M. Learoyd; W. Bannister; A. Fielding; A. Ravaud 2019 |
10.1007/s40262-019-00754-4 |
|
Pharmacokinetics of asunaprevir, daclatasvir and raltegravir in HCV/HIV co infected patients, with or without cirrhosis, and previously null responders to pegylated interferon plus ribavirin (ANRS HC30-QUADRIH study) A.M. Taburet; L. Piroth; H. Paniez; M. Simony; V. Furlan; A. Barrail-Tran; C. Vincent; E. Rosenthal; E. Billaud; H. Aumaitre; F. Bailly; M. Resch; L. Meyer; J.M. Molina 2014 |
|
|
Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma M. Luu; M. Bardou; P. Bonniaud; F. Goirand 2016 |
10.1080/17425255.2016.1248403 |
|
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C A. Desnoyer; D. Pospai; M.Patrick Le; A. Gervais; A. Heurgue-Berlot; A. Laradi; S. Harent; A. Pinto; D. Salmon; S. Hillaire; H. Fontaine; D. Zucman; A.M. Simonpoli; P. Muret; L. Larrouy; B.Bernard Chabert; D. Descamps; Y. Yazdanpanah; G. Peytavin 2016 |
10.1016/j.jhep.2016.02.044 |
|
Pharmacological Investigation of CC-LAAO, an L-Amino Acid Oxidase from Cerastes cerastes Snake Venom Z. Abdelkafi-Koubaa; I. ELBini-Dhouib; S. Souid; J. Jebali; R. Doghri; N. Srairi-Abid; K. Essafi-Benkhadir; O. Micheau; N. Marrakchi 2021 |
10.3390/toxins13120904 |
|
Pharmacological management of axial spondyloarthritis in adults E. Toussirot 2019 |
10.1080/14656566.2019.1617853, Early Access Date = {MAY 2019 |
|
Pharmacological management of axial spondyloarthritis in adults E. Toussirot 2019 |
10.1080/14656566.2019.1617853 |
|
Pharmacological modulators of autophagy activate a parallel noncanonical pathway driving unconventional LC3 lipidation E. Jacquin; S. Leclerc-Mercier; C. Judon; E. Blanchard; S. Fraitag; O. Florey 2017 |
10.1080/15548627.2017.1287653 |
|
Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease L. Vuitton; L. Peyrin-Biroulet 2020 |
10.1007/s40265-020-01266-3 |
|
Pharmacological therapies in post stroke recovery: recommendations for future clinical trials F. Chollet; S.C. Cramer; C. Stinear; L.J. Kappelle; J.C. Baron; C. Weiller; P. Azouvi; M. Hommel; U. Sabatini; T. Moulin; J. Tardy; M. Valenti; S. Montgomery; 2014 |
10.1007/s00415-013-7172-z |
|
Pharmacological treatment of patients with HFrEF: is it really optimized in case of CRT and/or ICD implantation? D. Logeart; R. Isnard; T. Damy; M. Salvat; J.C. Eicher; F. Roubille; C. Tribouilloy; F. Bauer; F. Picard; J.N. Trochu; G. Roul 2019 |
|
|
Pharmacological treatment of patients with HFrEF: is it really optimized in case of CRT and/or ICD implantation? D. Logeart; R. Isnard; T. Damy; M. Salvat; J.C. Eicher; F. Roubille; C. Tribouilloy; F. Bauer; F. Picard; J.N. Trochu; G. Roul 2019 |
|
|
Pharmacological treatment profiles in the FACE-BD cohort: An unsupervised machine learning study, applied to a nationwide bipolar cohort S. Brodeur; H. Terrisse; A. Pouchon; O. Godin; B. Aouizerate; V. Aubin; F. Bellivier; R. Belzeaux; T. Bougerol; P. Courtet; C. Dubertret; S. Gard; E. Haffen; C. Henry; M. Leboyer; E. Olie; P. Roux; L. Samalin; R. Schwan; B. Etain; J.L. Bosson; M. Polosan 2021 |
10.1016/j.jad.2021.02.036 |
|
Pharmacological treatments of anxiety disorders M. Guerriaud 2019 |
10.1016/j.actpha.2019.09.006 |
|
Pharmacy-based interventions to increase vaccine uptake: report of a multidisciplinary stakeholders meeting F. Ecarnot; G. Crepaldi; P. Juvin; J. Grabenstein; G. Del Giudice; L. Tan; S. O'Dwyer; S. Esposito; X. Bosch; G. Gavazzi; J. Papastergiou; J. Gaillat; R. Johnson; M. Fonzo; A. Rossanese; C. Suitner; J. Barratt; A. di Pasquale; S. Maggi; J.P. Michel 2019 |
10.1186/s12889-019-8044-y |
|
Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC) A. Cochet; P. Foucher; J. Vrigneaud; A. Bertaut; B. Coudert; P. Blom; J. Deloye; C. Coutant; G. Viot; J. Hoflack; P. Fumoleau; P. Genne; Y. Bouvet; C. Berthet; N. Isambert 2018 |
|
|
Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC) A. Cochet; P. Foucher; J. Vrigneaud; A. Bertaut; B. Coudert; P. Blom; J. Deloye; C. Coutant; G. Viot; J. Hoflack; P. Fumoleau; P. Genne; Y. Bouvet; C. Berthet; N. Isambert 2018 |
|
|
Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma P. Moreau; B. Kolb; M. Attal; D. Caillot; L. Benboubker; M. Tiab; C. Touzeau; X. Leleu; M. Roussel; C. Chaleteix; L. Planche; A. Chiffoleau; J. Fortin; H. Avet-Loiseau; J.Y. Mary; C. Hulin; T. Facon 2015 |
10.1182/blood-2015-02-626168 |
|
Phase 1B study of CC-486 (oral azacitidine) in tumors associated with a viral etiology D.D. Von Hoff; N. Isambert; J. Lopez-Martin; P.N. Munster; D.W. Rasco; J.C. Bendell; J.H.M. Schellens; J. Tomaro; R. Sarmiento; K. Liu; A. Nguyen; G.L. Bray; S.R. Hatty; J.F. DiMartino; C. Le Tourneau 2014 |
10.1016/S0959-8049(14)70677-X |
|
Phase 2 clinical study of onapristone (ONA) in patients (pts) with uterine endometrioid adenocarcinoma (EC) expressing the activated progesterone receptor (APR(pos)). J. Bonneterre; A. Leary; M. Campone; A. Italiano; M.P. Sablin; A. Floquet; D. Berton-Rigaud; C. Lhomme; A. Lesoin; D. Chocteau-Bouju; M. Fabbro; L. Favier; L. Gladieff; I. Ray-Coquard; A.Susannah Bexon; E.M. Gilles; J. Bisaha; A. Zukiwski; P.H. Cottu 2015 |
10.1200/jco.2015.33.15_suppl.tps5616 |
|
Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). M. Coleman; D. Belada; R.O. Casasnovas; R. Gressin; H.P. Lee; A. Mehta; J. Munoz; G. Verhoef; C. Corrado; D.James DeMarini; W. Zhao; X. Chen; K. Fay 2019 |
|
|
Phase 2 study of parsaclisib (INCB050465) for relapsed or refractory diffuse large b-cell lymphoma (DLBCL) (CITADEL-202). M. Coleman; D. Belada; R.O. Casasnovas; R. Gressin; H.P. Lee; A. Mehta; J. Munoz; G. Verhoef; C. Corrado; D.James DeMarini; W. Zhao; X. Chen; K. Fay 2019 |
|
|
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3K delta inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202) M. Coleman; D. Belada; R.O. Casasnovas; R. Gressin; H.P. Lee; A. Mehta; J. Munoz; G. Verhoef; C. Corrado; D.J. DeMarini; W. Zhao; J. Li; K. Fay 2021 |
10.1080/10428194.2020.1832660 |
|
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis J.F. Blanc; F. Khemissa; J.P. Bronowicki; C. Monterymard; J.M. Perarnau; V. Bourgeois; S. Obled; M. Ben Abdelghani; I. Mabile-Archambeaud; R. Faroux; J.F. Seitz; C. Locher; H. Senellart; A.L. Villing; F. Audemar; C. Costentin; G. Deplanque; S. Manfredi; J. Edeline Submitted |
10.1007/s12072-020-10120-3, Early Access Date = {JAN 2021 |
|
Phase 3 randomized study of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. P. Moreau; M. Attal; C. Hulin; M.C. Bene; A. Broijl; D. Caillot; M. Delforge; T. Dejoie; T. Facon; J. Lambert; X. Leleu; M. Macro; A. Perrot; S. Zweegman; T. Ahmadi; C. Chiu; L. Pei; J. Vermeulen; H. Avet-Loiseau; P. Sonneveld 2019 |